Company Focus
Novartis
Latest Novartis News
Pharmaceutical
Lewy body dementia (LBD) remains one of the most overlooked and complex neurodegenerative conditions, but momentum is building around a small group of experimental therapies, according to new research from DelveInsight. 11 July 2025
Related News
Insights
Company Spotlight
A global biotech developing of novel antibody-based drugs with innovative technologies.
Latest News & Features of interest to Novartis
Biotechnology
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (previously known as EG-70), Canadian company enGene’s lead investigational therapy for the treatment of high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). 26 June 2025
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the trade name for Neffy in the European Union) in Germany. 26 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Pharmaceutical
Nuvalent, a US biopharma developing precisely targeted therapies for clinically-proven kinase targets in cancer, has announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). 24 June 2025
Biotechnology
Revolution Medicines, a Californian oncology specialist developing targeted therapies for RAS-addicted cancers, has partnered with Royalty Pharma on $2 billion in flexible funding to support the former company’s independent global development and commercialization strategy and operations. 24 June 2025
Biotechnology
New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its subsidiary Libertas Bio has licensed gusacitinib to Sanofi, expanding the partnership between the companies. 24 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. 24 June 2025
Biotechnology
AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate the development of next-generation immunotherapies using Plectonic’s LOGIBODY platform. 24 June 2025
Latest In Brief for Novartis
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Ones To Watch News
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 12 July 2025
30 June 2025
17 June 2025
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze